Australia seeks domestic capability to produce mRNA vaccines | Inquirer News

Australia seeks domestic capability to produce mRNA vaccines

/ 03:53 PM May 21, 2021

A healthcare professional prepares a dose of the Pfizer coronavirus disease (COVID-19) vaccine as high-risk workers receive the first vaccines in the state of Victoria's rollout of the program, in Melbourne, Australia, February 22, 2021

FILE PHOTO: A healthcare professional prepares a dose of the Pfizer coronavirus disease (COVID-19) vaccine as high-risk workers receive the first vaccines in the state of Victoria’s rollout of the program, in Melbourne, Australia, February 22, 2021. REUTERS/Sandra Sanders/File Photo

CANBERRA — Australia has invited proposals from pharmaceutical firms to establish domestic manufacturing of mRNA vaccines, Prime Minister Scott Morrison said, as Canberra seeks to strengthen the nation’s ability to respond to future pandemics.

Earlier this month, the government announced it was in talks with Moderna to establish mRNA vaccine production, and on Friday Canberra said other companies had two months to submit their own proposals.

Article continues after this advertisement

“We have called for those proposals to come forward and to find out exactly what is needed from those proponents to see these facilities and capabilities being established here in Australia,” Morrison told reporters in Tasmania.

FEATURED STORIES

“(It) will be done as a partnership between industry and government,” he said, without elaborating.

Australia last year announced a A$1.5 billion ($1.2 billion) spending outlay to revitalize manufacturing across six sectors, including pharmaceuticals.

Article continues after this advertisement

Messenger ribonucleic acid (mRNA) vaccines prompt the body to make a protein that is part of the virus, triggering an immune response.

Article continues after this advertisement

Pfizer Inc and Moderna Inc use mRNA technology in their COVID-19 vaccines, which Australia will use to vaccinate people younger than 50 after Canberra restricted the use of a AstraZeneca vaccine due to blood clot concerns.

Article continues after this advertisement

Though Australia has fared much better than many other developed nations in containing the pandemic, with just under 30,000 cases and 910 deaths, the COVID-19 vaccine rollout has missed its initial dosage targets.

The national immunization drive has gathered pace recently with around a third of the 3.3 million doses administered given in the last three weeks.

Article continues after this advertisement

While industry observers note it will take years to fully establish domestic manufacturing facilities, lawmakers said it would put Australia at the forefront of cutting edge technology.

“It’s very likely as this technology and medical science develops it won’t be simply be vaccines but a range of therapeutic approaches for cancer, for cardiovascular diseases,” Christian Porter, Australia’s Minister for Innovation, told reporters in Perth.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Australia

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.